EP4574148A1 — Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension

USPTO Abstract

The present invention relates to a fixed combination medicinal product that is highly efficient and safe when being used in treating essential hypertension or/and reducing the risk of development of a condition associated with essential hypertension, and that additionally ensures excellent patient compliance. The fixed combination medicinal product comprises (a) telmisartan at a dose of 40 mg, amlodipine at a dose of 5 mg, and indapamide at a dose of 1.5 mg for modified release or at a dose of 2.5 mg for immediate release, (b) telmisartan at a dose of 80 mg, amlodipine at a dose of 5 mg, and indapamide at a dose of 1.5 mg for modified release or at a dose of 2.5 mg for immediate release, or (c) telmisartan at a dose of 80 mg, amlodipine at a dose of 10 mg, and indapamide at a dose of 1.5 mg for modified release or at a dose of 2.5 mg for immediate release. The fixed combination medicinal product is administered once or twice, preferably once a day and is used as (α) a first-line antihypertensive therapy for a hypertensive patient, (β) a second-line antihypertensive therapy for a hypertensive patient who is a non-responder to a previous antihypertensive therapy, or (γ) a substitution antihypertensive therapy for a hypertensive patient whose blood pressure is adequately controlled by a previous antihypertensive therapy.